% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • verityvoila verityvoila Nov 20, 2012 4:19 PM Flag

    Insights on other correctors

    The CFF announced yesterday up to a $58 M investment in pre-clinical research to Pfizer over the next six years for correctors aimed at df508. Looks like Pfizer got into the arena by buying FoldRX. Looking for some insights:
    1) Anyone know what FoldRX had on its plate re correctors?
    2) Are there multiple high-thoroughput mechanisms for screening small molecules? In other words, wil Pfizer and Vertex be screening using the same or different methods?
    3) Do different pharmas "own" or have "access" to different molecules, such that Pfizer could be testing different ones or would they both be looking at the same universe of molecules.
    4) Any thoughts on the timing? CFF indicated goal at end of 6 years was to be in clinical studies. Could it be faster?
    5) What else am I missing?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
133.06+1.09(+0.83%)Nov 27 1:00 PMEST